Nautilus Biotechnology Unveils Reproducible Single-Molecule Proteomics Data at Buck Institute

Reuters
2025/11/03
Nautilus Biotechnology Unveils Reproducible Single-Molecule Proteomics Data at Buck Institute

Nautilus Biotechnology Inc. has announced the successful installation and testing of its first external field evaluation unit at the Buck Institute for Research on Aging. Over six months, researchers at the Buck Institute used Nautilus' next-generation single-molecule proteomics platform to generate highly reproducible data from neurodegenerative disease samples, including novel insights into tau proteoforms. These results validate the platform's robust performance and its potential to advance understanding of aging and neurodegeneration, such as Alzheimer's disease. The scientific findings from this collaboration will be presented at the 2025 HUPO World Congress seminar, "Redefining Proteomics with Single-Molecule Iterative Mapping," scheduled for November 10, 2025, in Toronto.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566730-en) on November 03, 2025, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10